<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01631487</url>
  </required_header>
  <id_info>
    <org_study_id>CR100890</org_study_id>
    <secondary_id>39439335PAI1005</secondary_id>
    <nct_id>NCT01631487</nct_id>
  </id_info>
  <brief_title>A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-39439335 in Healthy Japanese and Caucasian Adult Male Participants</brief_title>
  <official_title>A Double-Blind, Randomized, Placebo-Controlled, Sequential Group, Single Ascending and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-39439335 in Healthy Japanese and Caucasian Adult Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Research &amp; Development, LLC</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the safety, tolerability, and pharmacokinetics of
      JNJ-39439335 in healthy Japanese and Caucasian adult male participants in Part 1, and in
      healthy Japanese adult male participants in Part 2.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a double-blind (neither physician nor participant knows the treatment that the
      participant receives), randomized (the study drug is assigned by chance), placebo-controlled
      study (placebo is an inactive substance that is compared with a drug to test whether the drug
      has a real effect in a clinical trial). The study consists of 2 Parts. In Part 1, three
      groups of healthy Japanese men and 3 groups of healthy Caucasian men will receive a single
      oral dose of JNJ-39439335 or placebo on Day 1. Each group will include 8 participants. The
      study duration of Part 1 for each participant is approximately 8 weeks: screening phase of up
      to 28 days prior to dose, treatment phase of 14 days, and a follow-up phase of 14 to16 days.
      In Part 2, three groups of healthy Japanese men will receive once-daily doses of either
      JNJ-39439335 or placebo for 21 days. Each group will include 12 participants. The study
      duration of Part 2 for each participant is approximately 11 weeks: screening phase of up to
      28 days prior to dose, treatment phase of 21 days, and a follow-up phase of approximately 28
      days. During the treatment phases, the participants will remain in the study unit. Blood
      samples and urine will be collected for drug concentration measurements and laboratory safety
      assessments.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma concentrations of JNJ-39439335 (Part 1)</measure>
    <time_frame>up to 14 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Urine concentrations of JNJ-39439335 (Part 1)</measure>
    <time_frame>up to 5 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentrations of JNJ-39439335 (Part 2)</measure>
    <time_frame>up to 21 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Urine concentrations of JNJ-39439335 (Part 2)</measure>
    <time_frame>up to 21 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events (Part 1)</measure>
    <time_frame>Approximately 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events (Part 2)</measure>
    <time_frame>Approximately 11 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Actual">86</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Japanese Group 1: JNJ-39439335/placebo (Part 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Japanese Group 2: JNJ-39439335/placebo (Part 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Japanese Group 3: JNJ-39439335/placebo (Part 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Caucasian Group 1: JNJ-39439335/placebo (Part 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Caucasian Group 2: JNJ-39439335/placebo (Part 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Caucasian Group 3: JNJ-39439335/placebo (Part 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Japanese Group 1: JNJ-39439335/placebo (Part 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Japanese Group 2: JNJ-39439335/placebo (Part 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Japanese Group 3: JNJ-39439335/placebo (Part 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JNJ-39439335 10 mg</intervention_name>
    <description>Multiple (once daily for 21 days) oral doses of JNJ-39439335 10 mg.</description>
    <arm_group_label>Japanese Group 1: JNJ-39439335/placebo (Part 1)</arm_group_label>
    <arm_group_label>Caucasian Group 1: JNJ-39439335/placebo (Part 1)</arm_group_label>
    <arm_group_label>Japanese Group 1: JNJ-39439335/placebo (Part 2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JNJ-39439335 25 mg</intervention_name>
    <description>Multiple (once daily for 21 days) oral doses of JNJ-39439335 25 mg.</description>
    <arm_group_label>Japanese Group 2: JNJ-39439335/placebo (Part 1)</arm_group_label>
    <arm_group_label>Caucasian Group 2: JNJ-39439335/placebo (Part 1)</arm_group_label>
    <arm_group_label>Japanese Group 2: JNJ-39439335/placebo (Part 2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JNJ-39439335 50 mg</intervention_name>
    <description>Multiple (once daily for 21 days) oral doses of JNJ-39439335 50 mg.</description>
    <arm_group_label>Japanese Group 3: JNJ-39439335/placebo (Part 1)</arm_group_label>
    <arm_group_label>Caucasian Group 3: JNJ-39439335/placebo (Part 1)</arm_group_label>
    <arm_group_label>Japanese Group 3: JNJ-39439335/placebo (Part 2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Multiple (once daily for 21 days) oral doses of matching placebo.</description>
    <arm_group_label>Japanese Group 1: JNJ-39439335/placebo (Part 1)</arm_group_label>
    <arm_group_label>Japanese Group 2: JNJ-39439335/placebo (Part 1)</arm_group_label>
    <arm_group_label>Japanese Group 3: JNJ-39439335/placebo (Part 1)</arm_group_label>
    <arm_group_label>Caucasian Group 1: JNJ-39439335/placebo (Part 1)</arm_group_label>
    <arm_group_label>Caucasian Group 2: JNJ-39439335/placebo (Part 1)</arm_group_label>
    <arm_group_label>Caucasian Group 3: JNJ-39439335/placebo (Part 1)</arm_group_label>
    <arm_group_label>Japanese Group 1: JNJ-39439335/placebo (Part 2)</arm_group_label>
    <arm_group_label>Japanese Group 2: JNJ-39439335/placebo (Part 2)</arm_group_label>
    <arm_group_label>Japanese Group 3: JNJ-39439335/placebo (Part 2)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Japanese or Caucasian participants

          -  Nonsmoker

          -  Body Mass Index (BMI) of 18 to 30 kg/m2, inclusive, and body weight not less than 50
             kg

          -  Healthy on the basis of a physical examination, vital signs, hematology, coagulation,
             serum chemistry (including liver function tests) and urinalysis

          -  Willing to adhere to the prohibitions and restrictions specified by the study protocol

        Exclusion Criteria:

          -  Oral temperatures &gt; 37.5 Celsius degrees

          -  Participants who have occupations or hobbies in which they are routinely exposed to
             situations in which they could sustain thermal burns

          -  Abnormal electrocardiogram (ECG) results

          -  Clinically significant abnormal values for hematology, clinical chemistry or
             urinalysis

          -  History of or current clinically significant medical illness that the investigator
             considers should exclude the participant or that could interfere with the
             interpretation of the study results
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Research &amp; Development, LLC Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Research &amp; Development, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Cypress</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 27, 2012</study_first_submitted>
  <study_first_submitted_qc>June 27, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 29, 2012</study_first_posted>
  <last_update_submitted>June 24, 2013</last_update_submitted>
  <last_update_submitted_qc>June 24, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 25, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy</keyword>
  <keyword>JNJ-39439335</keyword>
  <keyword>Japanese</keyword>
  <keyword>Caucasian</keyword>
  <keyword>Male</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

